PMID- 25998232
OWN - NLM
STAT- MEDLINE
DCOM- 20160524
LR  - 20240109
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 12
IP  - 3
DP  - 2015 Sep
TI  - Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer 
      cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin 
      pathways.
PG  - 3446-3452
LID - 10.3892/mmr.2015.3804 [doi]
AB  - Fucoidan, a sulfated polysaccharide, has a variety of biological activities, 
      including anti-cancer, anti-angiogenic and anti-inflammatory effects. However, 
      the underlying mechanisms of fucoidan as an anti‑cancer agent remain to be 
      elucidated. The present study examined the anti‑cancer effect of fucoidan on 
      HT‑29 human colon cancer cells. The cell growth of HT29 cells was significantly 
      decreased following treatment with fucoidan (200 microg/ml). In addition, fucoidan 
      inhibited the migration of HT‑29 cells by decreasing the expression levels of 
      matrix metalloproteinase‑2 in a dose‑dependent manner (0‑200 microg/ml). The 
      underlying mechanism of these inhibitory effects included the downregulation of 
      phosphoinositide 3‑kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) by 
      treatment with fucoidan. Furthermore, fucoidan increased the expression of 
      cleaved caspase‑3 and decreased cancer sphere formation. The present study 
      suggested that fucoidan exerts an anti‑cancer effect on HT‑29 human colon cancer 
      cells by downregulating the PI3K‑Akt‑mTOR signaling pathway. Therefore, fucoidan 
      may be a potential therapeutic reagent against the growth of human colon cancer 
      cells.
FAU - Han, Yong-Seok
AU  - Han YS
AD  - Laboratory for Medical Science Research Institute, Soonchunhyang University, 
      Seoul Hospital, Seoul 336‑745, Republic of Korea.
FAU - Lee, Jun Hee
AU  - Lee JH
AD  - Department of Physiology, Laboratory for Vascular Medicine and Stem Cell Biology, 
      Medical Research Institute, School of Medicine, Pusan National University, 
      Yangsan, Gyeongsangnam-do 626‑870, Republic of Korea.
FAU - Lee, Sang Hun
AU  - Lee SH
AD  - Laboratory for Medical Science Research Institute, Soonchunhyang University, 
      Seoul Hospital, Seoul 336‑745, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150521
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Polysaccharides)
RN  - 9072-19-9 (fucoidan)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Movement/*drug effects
MH  - Cell Proliferation/*drug effects
MH  - Cell Survival
MH  - Drug Screening Assays, Antitumor
MH  - HT29 Cells
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Polysaccharides/*pharmacology
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/*drug effects
MH  - Spheroids, Cellular/drug effects
MH  - TOR Serine-Threonine Kinases/metabolism
PMC - PMC4526071
EDAT- 2015/05/23 06:00
MHDA- 2016/05/25 06:00
PMCR- 2015/05/21
CRDT- 2015/05/23 06:00
PHST- 2014/08/08 00:00 [received]
PHST- 2015/04/24 00:00 [accepted]
PHST- 2015/05/23 06:00 [entrez]
PHST- 2015/05/23 06:00 [pubmed]
PHST- 2016/05/25 06:00 [medline]
PHST- 2015/05/21 00:00 [pmc-release]
AID - mmr-12-03-3446 [pii]
AID - 10.3892/mmr.2015.3804 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Sep;12(3):3446-3452. doi: 10.3892/mmr.2015.3804. Epub 2015 May 
      21.